Rheumatology and immunology coordination
High-volume, high-cadence specialty coordination — biologics and biosimilars for immune-mediated disease, with the dosing discipline of the treating physician in the lead.
Rheumatology and dermatology coordination is the highest-volume specialty category at the patient-chart level. The therapies are mostly subcutaneous biologics or biosimilars, the indications spread across plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, atopic dermatitis, hereditary angioedema and related immune-mediated diseases. What varies is the specific molecule, the dosing interval, and whether the patient is initiating or continuing.
Therapy classes
- IL-17 dual inhibition — Bimzelx is the only approved biologic that blocks both IL-17A and IL-17F; indications extend across plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axSpA, and hidradenitis suppurativa.
- IL-12/23 p40 inhibition (biosimilars) — Selarsdi is an ustekinumab biosimilar for psoriasis and psoriatic arthritis; biosimilar access broadens global availability of a cornerstone therapy.
- Adalimumab biosimilars — Simlandi covers the adalimumab label spectrum.
- Hereditary angioedema — on-demand plasma kallikrein inhibitors (Ekterly oral; Kalbitor subcutaneous, administered under healthcare-professional supervision).
- Transplant-related immunology — Rezurock for chronic graft-versus-host disease after two prior lines of systemic therapy.
What the treating rheumatologist or dermatologist keeps
The disease monitoring, dose titration, injection training, and the shared decision on biologic class remain with the treating physician and the local care team. We coordinate the import, the dispensing partner's review, the cold-chain delivery, and the paper trail.